Form 4: AbCellera Biologics Chief Legal Officer Acquires 832,033 Share Options

Tryn Stimart, Chief Legal Officer of AbCellera Biologics, has been granted 832,033 share options with a strike price of $2.93, vesting over four years.

Summary

• Tryn Stimart, the Chief Legal Officer of AbCellera Biologics, was granted 832,033 share options on January 1, 2025.
• The options have an exercise price of $2.93 per share.
• These options vest monthly over a four-year period, starting January 1, 2026, contingent on continuous service to the company.
• Following this transaction, Mr. Stimart directly owns 4,106,747 common shares and 832,033 share options.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally positive for aligning management and shareholder interests. There are no negative implications.

Positives

• The grant of share options aligns the Chief Legal Officer's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

This is a standard practice for incentivizing key executives in publicly traded companies, particularly in the biotech sector.

Comparison to Industry Standards

• Share option grants are a common form of compensation for executives in publicly traded companies, especially in the biotech industry.
• The vesting schedule of four years is also typical, aligning executive interests with long-term company performance.
• Companies like Regeneron, Amgen, and Gilead Sciences also use similar equity-based compensation plans for their executives.

Stakeholder Impact

• The share option grant aligns the Chief Legal Officer's interests with those of the shareholders, potentially leading to better long-term performance.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

share options, insider trading, executive compensation, AbCellera Biologics, ABCL, Tryn Stimart, Chief Legal Officer, equity